Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss some of the most recent data from the landmark trial, DAPA-HF.
Prof Petrie describes the exploratory analysis of a randomised trial of patients with HFrEF and its results. Dr Kosiborod and Prof Petrie talk about the benefits of treatment in the context of background therapies and the utilisation of guideline therapies. Dr Kosiborod asks Prof Petrie about the clinical implementation of dapagliflozin and the future of heart failure management.
Recorded remotely from Glasgow and Kansas City, 2020.
This discussion was supported by an unrestricted educational grant from Novo Nordisk.